Skip to content

Exploratory Study on the Effects of Coix Seed Intake on Blood Pressure in Individuals with Elevated Blood Pressure

Exploratory Study on the Effects of Coix Seed Intake on Blood Pressure in Individuals with Elevated Blood Pressure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124219
Enrollment
Unknown
Registered
2026-05-08
Start date
2026-05-11
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

High-dose group:High-dose coix seed powder
Control group:Rice powder
Low-dose group:Low-dose coix seed powder

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age between 30 and 55 years; 2. Within the past 3 months, systolic blood pressure of 130–159 mmHg and/or diastolic blood pressure of 80–99 mmHg, measured on three different occasions on non-consecutive days; 3. Willing to participate in this study and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with secondary hypertension; 2. Use of antihypertensive medications or other drugs that may directly affect blood pressure within the past 6 months; 3. Pregnant or breastfeeding women, or women planning to become pregnant during the study period; 4. Individuals with allergy to coix seed; 5. Individuals with abnormal glucose metabolism, including impaired glucose tolerance or diabetes mellitus; 6. Patients with serious cardiovascular or cerebrovascular diseases, such as myocardial infarction or unstable angina; 7. Patients with severe hepatic or renal dysfunction, or endocrine disorders such as hyperthyroidism, hypothyroidism, or hypercortisolism; 8. Patients with malignancies or autoimmune diseases; 9. Vulnerable populations, including individuals with mental illness, cognitive impairment, critically ill conditions, or illiteracy; 10. Participation in other clinical studies within the past 3 months; 11. Any other conditions that, in the opinion of the investigators, make the participant unsuitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
Blood pressure;

Secondary

MeasureTime frame
Body composition;Blood biochemistry;Blood pressure;Non-targeted metabolomics;Complete blood count;Adverse outcome;Ambulatory blood pressure;

Countries

China

Contacts

Public ContactHui Liu

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

lhui_991@yeah.net+86 571 86006653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026